Latest News and Press Releases

Aicuris today announced positive results from its pivotal Phase 3 trial evaluating pritelivir in immunocompromised patients with refractory HSV

Austin, United States, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Human Vaccines Market Size & Growth Analysis: According to SNS Insider, the Human Vaccines Market size was valued at USD 44.26 billion...

Neura cognitive health supplement disclosures updated. Ingredient transparency, label literacy & research context for consumers Feb 2026.

TruFull CBD Gummies disclosure update: hemp-derived, third-party tested, THC-free verification. Full-spectrum CBD supplement info for 2026.

Max Force Power Male Enhancement Gummies product disclosures updated. Informational overview of ingredient transparency & consumer evaluation.

MEN Balance Pro 2026 disclosure overview: refund policy, retailer info, ingredient transparency & what consumers verify when researching supplements.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options If you purchased or...

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on...

New York City, NY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Intro In a timely development that is drawing strong attention across the men’s wellness sector, a new supplement—Men Balance Pro—has been...

Intro  New York City, NY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- In response to growing global attention on proactive men’s wellness and age-related vitality support, Garaherb has emerged in 2026 as a...

Croissance de 6,5 % du chiffre d’affaires 2025 Confirmation de la feuille de route Fleurieux-sur-l’Arbresle - France - le 4 février 2026 à 18h. Safe Group publie son chiffre d’affaires annuel...

NEW YORK, NY, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Felix Hesse, who overcame years of debilitating health complications through nutritional science, launched Best Supplements to address transparency...

“Bioprocess Filtration: Global Markets” is estimated to grow from $8.4 billion in 2025 to $15.6 billion by 2030, at a CAGR of 13.1% from 2025 through 2030.

MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Summit Products Group...

Dewpoint doses first patient in Phase 1a/2a trial of DPTX3186, an FDA Fast Track, Orphan-designated beta-catenin modulator for advanced solid tumors.

Market insights predict the global AI in wound care market to increase from USD 0.64 billion in 2024 to USD 12.9 billion by 2034, at a CAGR of 35.03%.

GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

The diabetic neuropathy treatment market size is set to expand from USD 4.71 billion in 2024 to USD 9.93 billion by 2034, with a CAGR of 7.75%.

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant...

Investors who lost money in CORT after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and...

DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that...

MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...

BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is...

SANTA ANA, CALIFORNIA, Feb. 04, 2026 (GLOBE NEWSWIRE) -- PrimeGen US, Inc. (“PrimeGen US" or the "Company”), a pioneering biotech company advancing innovative stem cell and exosome therapies, today...

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical data...

GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for...

FORT MILL, S.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a medical device company specializing in advanced electrophysiology solutions, today announced a...

PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to...

This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to...

CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living...

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe...

LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...

Austin, United States, Feb. 04, 2026 (GLOBE NEWSWIRE) -- 3D Bioprinting Market Size & Growth Analysis: According to SNS Insider, the 3D Bioprinting Market was valued at USD 2.15 billion in...

SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today...

Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM® System to address blood pressure instability after spinal cord injury (SCI)Blood...

Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf...

Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from...

Shenzhen, China, Feb. 04, 2026 (GLOBE NEWSWIRE) -- In 2025, Geekvape and Geek Bar achieved a major breakthrough on the global design stage, driven by years of deep investment in design capability...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their...

Herz P1 Smart Scale: 8-electrode body composition device with 56 metrics, no subscription fees. Updated product information for home wellness tracking.

SANGAMO THERAPEUTICS PRESENTS DETAILED DATA FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE AT WORLDSYMPOSIUM 2026

BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research

Washington, D.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today applauded the bipartisan passage of the annual federal funding bill that sustains critical...

New York City, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Public interest in natural approaches to male vitality, prostate comfort, and hormonal balance is at an all-time high in 2026, driven by...

New York City, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Public interest in natural approaches to visual comfort and clarity is at an all-time high in 2026, driven by increased screen use,...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of REGENXBIO Inc. (“Regenxbio” or the “Company”) (NASDAQ: RGNX).  Such investors are advised...